AstraZeneca and its division MedImmune have secured fast tract status for their respiratory syncytial virus (RSV) therapeutic, MEDI8897, from both the US and European regulatory authorities.

The US Food and Drug Administration (FDA) granted breakthrough therapy designation (BTD) to the drug, expediting its development and regulatory review.

In addition, the European Medicines Agency (EMA) has granted it PRIME eligibility, which will support development and speed up assessment to bring the drug to market faster.

MEDI8897 is an extended half-life RSV F monoclonal antibody being developed to prevent lower respiratory tract infection (LRTI) caused due to RSV in newborns and infants.

The drug is also being developed to enable only one dose during an average five-month RSV season.

AstraZeneca is developing MEDI8897 in alliance with Sanofi Pasteur, under an agreement signed by the companies in March 2017.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“MEDI8897 has the potential to address an important unmet need for infants, families and caregivers.”

The FDA and EMA decisions are based on results obtained during the primary analysis of a Phase IIb clinical trial performed to evaluate the safety and efficacy of MEDI8897.

Primary endpoint of the trial was met, demonstrating a statistically-significant decrease in the medically-attended LRTI incidence caused by RSV for 150 days post dosing in healthy preterm infants.

MEDI8897 is also being studied in a Phase III trial involving late preterm and healthy full-term infants.

AstraZeneca R&D BioPharmaceuticals executive vice-president Mene Pangalos said: “MEDI8897 is our next-generation preventive medicine for respiratory syncytial virus, which has the potential to address an important unmet need for infants, families and caregivers.”

Recently, the company obtained positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for a new indication of its Forxiga (dapagliflozin) medicines as an oral adjunct therapy to insulin in type-1 diabetes (T1D) patients.

Forxiga, which is indicated for adults, is a selective sodium glucose cotransporter-2 (SGLT2) inhibitor. The therapeutic is also being reviewed in the US and Japan.